Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group
- Author(s)
- van de Loosdrecht, AA; Kern, W; Porwit, A; Valent, P; Kordasti, S; Cremers, E; Alhan, C; Duetz, C; Dunlop, A; Hobo, W; Preijers, F; Wagner-Ballon, O; Chapuis, N; Fontenay, M; Bettelheim, P; Eidenschink-Brodersen, L; Font, P; Johansson, U; Loken, MR; Te Marvelde, JG; Matarraz, S; Ogata, K; Oelschlaegel, U; Orfao, A; Psarra, K; Subira, D; Wells, DA; Bene, MC; Della Porta, MG; Burbury, K; Bellos, F; van der Velden, VHJ; Westers, TM; Saft, L; Ireland, R;
- Details
- Publication Year 2023-01,Volume 104,Issue #1,Page 77-86
- Journal Title
- Cytometry Part B: Clinical Cytometry
- Publication Type
- Research article
- Abstract
- This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.
- Publisher
- Wiley
- Keywords
- Humans; Flow Cytometry; *Myelodysplastic Syndromes/diagnosis; Eln; consensus; myelodysplastic syndromes; standardization
- Department(s)
- Clinical Haematology
- PubMed ID
- 34897979
- Publisher's Version
- https://doi.org/10.1002/cyto.b.22044
- Open Access at Publisher's Site
https://doi.org/10.1002/cyto.b.22044- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-06-15 07:24:51
Last Modified: 2023-06-15 07:25:48